Rhumbline Advisers Buys 2,547 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Rhumbline Advisers raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 173,167 shares of the biopharmaceutical company's stock after purchasing an additional 2,547 shares during the quarter. Rhumbline Advisers owned 0.16% of Regeneron Pharmaceuticals worth $109,828,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research note on Friday, May 30th. UBS Group cut their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $844.48.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of REGN stock traded down $1.86 on Thursday, reaching $483.07. 1,790,802 shares of the company's stock traded hands, compared to its average volume of 856,101. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $52.15 billion, a P/E ratio of 12.62, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The business's 50 day moving average price is $572.23 and its two-hundred day moving average price is $659.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.73%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.